摘要
目的评价西布曲明对肥胖的2型糖尿病患者血糖的影响及安全性。方法为随机、双盲、安慰剂对照的临床研究。完成观察病例31例,其中西布曲明组15例,安慰剂组16例。结果西布曲明组的A1C用药第6个月末(7.08±1.69)%明显低于试验初期(7.69±1.26)%。在用药第5个月末的空腹血糖水平(7.81±1.55)mmol/L明显低于对照组(9.79±3.55)mmol/L。在用药第2个月末和第4个月末西布曲明组的体重〔分别为(69.04±8.78)?和(68.65±8.44)?〕明显低于对照组〔分别为(74.03±15.34)?和(74.07±15.44)?〕。西布曲明组在用药第3个月末甘油三酯〔(0.43±0.58)mmol/L〕和低密度脂蛋白〔(2.28±0.65)mmol/L〕明显低于安慰剂组〔分别为(0.80±0.72)mmol/L和(2.50±0.35)mmol/L〕。两组不良反应发生率没有显著差异。结论盐酸西布曲明可以进一步改善肥胖的2型糖尿病患者的血糖,糖尿病患者使用盐酸西布曲明安全有效。
Objective To assess the safety and effect of sibutramine on the blood glucose in patients with type 2 diabetes and obesity. Methods It is a randomized placebo-controlled clinical trial with 31 patients enrolled. Results The A1C at 6 month of sibutramine group was lower than that of control group. The fasting glucose at 5 month, the body weight at 2 month and 4 month, the triglyceride and low density lipoprotein at 3 month were lower than those of control group. The adverse effects were the same in the two groups. Conclusion Sibutramine further improve the glucose control and it is safe and effective in obese diabetic patients.
出处
《重庆医学》
CAS
CSCD
2005年第8期1180-1181,1183,共3页
Chongqing medicine
关键词
西布曲明
肥胖
2型糖尿病
血糖
sibutramine
obesity
type 2 diabet es
blood glucose
